Methyl 5-amino-4-methyl-1h-pyrazole-3-carboxylate | 2489342-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Methyl 5-amino-4-methyl-1h-pyrazole-3-carboxylate
• 英文别名: methyl 3-amino-4-methyl-1H-pyrazole-5-carboxylate
• CAS: 2489342-76-7
• 化学式: C₆H₉N₃O₂
• 分子量: 155.15
• InChiKey: ZQZMLNHVAVSFGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  81
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES<br/>[FR] DÉRIVÉS DE PYRIMIDONE À CYCLES FUSIONNÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B OU DE MALADIES INDUITES PAR LE VIRUS DE L'HÉPATITE B
  申请人：JANSSEN SCIENCES IRELAND UNLIMITED CO

  公开号：WO2020182990A1

  公开（公告）日：2020-09-17

  The present application relates to compounds according to Formula (I), pharmaceutical compositions comprising at least one of said compounds, their use as a medicament, and their use in treating chronic hepatitis B virus (HBV) infection. The disclosure further pertains to methods for preparing compounds according to Formula (I).

  本申请涉及按照式(I)的化合物，包括至少一种所述化合物的药物组合物，其作为药物的用途，以及其在治疗慢性乙型肝炎病毒（HBV）感染中的用途。该公开还涉及按照式(I)制备化合物的方法。
• Dihydropyrazolo(3,4-b)pyridine derivatives and production thereof
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0107619A1

  公开（公告）日：1984-05-02

  Dihydropyrazolo[3,4-bipyridine derivatives represented by the general formula: wherein X and X each is hydrogen, nitro, or halogen which may be located at the position or positions 2, 3, and/or 6; R1 is alkyl; R2 is hydrogen, alkyl, cycloalkyl, or phenyl; R3 is hydrogen, straight or branched chain alkyl, or cycloalkyl which may be substituted by alkyl, substituted or unsubstituted phenyl, aralkyl, alkoxycarbonyl, or 5- or 6- membered heterocyclic group containing an oxygen or nitrogen, having calcium-antagonistic action are useful in treatment of diseases in the circulatory system such as angina pectoris, hypertension, cerebrovascular dysfunction, arrhythmia, and so on with no adverse reaction like negative inotropic action; prepared by the Michael addition and concurrent cyclization reaction of 2-acetyl cinnamic acid derivatives with 5-aminopyrazole derivatives.

  由通式代表的二氢吡唑并[3,4-联吡啶]衍生物： 其中 X 和 X 各为氢、硝基或卤素，可位于位置 2、3 和/或 6； R1 是烷基 R2 是氢、烷基、环烷基或苯基； R3 是氢、直链或支链烷基，或可被烷基、取代或未取代的苯基、芳基、烷氧羰基或含氧或氮的 5 或 6 位杂环基取代的环烷基。 通过 2-乙酰肉桂酸衍生物与 5-氨基吡唑衍生物的迈克尔加成和同时环化反应制备。
• 8-substituted pyrazolopentathiepins and related compounds
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0138622A2

  公开（公告）日：1985-04-24

  Heteropentathiepins including pyrazolopentathiepins substituted in the 8-position; intermediate pyrazolo-1,2,3-thiadiazoles, pyrazolothiazathiolium chlorides, and 5-substituted aminopyrazoles; process for making the pentathiepins by reacting the corresponding 1,2,3-thiadiazoles with sulfur at elevated temperatures; and use of the pentathiepins as fungicides or as sulfur sensitizers in photographic emulsions.

  异戊硫杂环戊烷，包括在 8 位被取代的吡唑戊硫杂环戊烷；吡唑-1,2,3-噻二唑、吡唑噻二唑鎓氯化物和 5-取代氨基吡唑的中间体；通过在高温下使相应的 1,2,3-噻二唑与硫发生反应来制造戊硫杂环戊烷的工艺；以及将戊硫杂环戊烷用作杀真菌剂或感光乳剂中的硫增感剂。
• Amino-quinolines as kinase inhibitors
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US10220030B2

  公开（公告）日：2019-03-05

  Disclosed are compounds having the formula: wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.

  所公开的是具有以下式子的化合物 其中 R1、R2、R3 和 Z 如本文所定义，以及制造和使用它们的方法。
• DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS
  申请人：Pharmacia S.p.A.

  公开号：EP0722446A1

  公开（公告）日：1996-07-24